One-minute decision guide
The simple evidence-based answer
Start with the clinical problem, not a target “youthful” number. For menopause symptoms, discuss age, time since menopause, uterus status, clot and cancer history, route and dose; estrogen with an intact uterus usually requires endometrial protection. For testosterone, require compatible symptoms plus repeat accurate morning levels and evaluation of the cause. Discuss fertility before TRT because it can suppress sperm production. Use regulated products, the lowest effective dose for the goal, scheduled monitoring and periodic reassessment.See reference 1,See reference 2,See reference 3
The 10 rules to remember
- Use hormone replacement therapy only for a clearly defined problemSee reference 1
- Start with the lowest-burden evidence-based optionSee reference 2
- Record a baseline before changing anythingSee reference 3
- Do not confuse a biological mechanism with a proven health outcomeSee reference 4
- Do not let hormone replacement therapy replace established careSee reference 5
- Use qualified clinical oversight when the intervention is medicalSee reference 6
- Stop when harms, abnormal symptoms or a worse trend appearSee reference 7
- Judge benefit with measurements that matter to the original goalSee reference 8
- Reassess cost, burden and uncertainty after the planned trialSee reference 9
- Avoid protocols based only on testimonials, influencers or clinic marketingSee reference 10
First principles: what this can actually change
Hormones are systemic signals with benefits and harms across multiple tissues; replacing a true deficiency differs from pushing levels above physiological need.See reference 1,See reference 2
Age-related population averages do not by themselves define a disease or treatment target.See reference 3,See reference 4
Route, dose, timing, co-therapy and baseline risk can materially change the benefit-risk balance.See reference 5,See reference 6
A practical decision protocol
| Stage | What to do | Why it matters |
|---|---|---|
| 1. Diagnose | Confirm symptoms, appropriate labs and underlying cause | Numbers without context cause overtreatmentSee reference 1,See reference 2 |
| 2. Stratify risk | Review fertility, cancer, clotting, sleep apnea and cardiovascular history | Contraindications are therapy-specificSee reference 3,See reference 4 |
| 3. Choose product | Use regulated formulations and the least burdensome effective route | Custom blends add uncertaintySee reference 5,See reference 6 |
| 4. Monitor | Track symptom response and therapy-specific safety markers | Benefit without safety data is incompleteSee reference 7,See reference 8 |
Timing, dose and frequency
| Decision | Practical answer |
|---|---|
| Testosterone testing | Use repeat morning fasting total testosterone and free testosterone when indicated.See reference 1,See reference 2 |
| Menopause initiation | Benefit-risk is generally more favorable for healthy symptomatic women under 60 or within 10 years of menopause, absent contraindications.See reference 3,See reference 4 |
| After starting | Review response and adverse effects at the clinician-defined interval, then periodically.See reference 5,See reference 6 |
| Long term | Continue only while goals and benefit-risk remain favorable; there is no universal stopping age.See reference 7,See reference 8 |
What to measure
| Signal | How | Interpretation |
|---|---|---|
| Target symptoms | Use a baseline severity and function score | Treatment should improve the reason it was startedSee reference 1,See reference 2 |
| Hormone level when relevant | Use accurate timed laboratory testing | Avoid dose chasing beyond the therapeutic goalSee reference 3,See reference 4 |
| Blood count and prostate context for TRT | Follow guideline-based hematocrit and prostate monitoring | Erythrocytosis and prostate risk need actionSee reference 5,See reference 6 |
| Bleeding and breast or endometrial context for MHT | Follow symptom and screening guidance | Unexpected bleeding requires evaluationSee reference 7,See reference 8 |
What the evidence actually shows
The Menopause Society states that hormone therapy is the most effective treatment for vasomotor symptoms and prevents bone loss, with individualized risk by age, timing, route and regimen.See reference 1,See reference 2
The Endocrine Society recommends testosterone only for men with compatible symptoms and unequivocally, consistently low levels after cause evaluation.See reference 3,See reference 4
Neither guideline supports population screening or hormone treatment solely to reverse normal aging.See reference 5,See reference 6
Evidence strength by claim
| Claim | Confidence | Important boundary |
|---|---|---|
| Relieves menopause vasomotor symptoms | High | Regimen and individual risk matterSee reference 1,See reference 2 |
| Treats pathological male hypogonadism | High | Requires symptoms, repeated low levels and causeSee reference 3,See reference 4 |
| Improves fertility in men | Low | TRT commonly suppresses spermatogenesisSee reference 5,See reference 6 |
| Prevents aging in healthy adults | Very low | No validated anti-aging outcomeSee reference 7,See reference 8 |
Limits and common overclaims
HRT can mean menopause therapy, testosterone therapy or unregulated compounded mixtures; these are not interchangeable.See reference 4,See reference 7
Symptoms attributed to hormones may come from sleep apnea, depression, thyroid disease, medicines or other conditions.See reference 5,See reference 8
Observational clinic outcomes are vulnerable to healthy-user and selection bias.See reference 6,See reference 9
A four-step implementation plan
- 1. Confirm symptoms, appropriate labs and underlying causeSee reference 1
- 2. Review fertility, cancer, clotting, sleep apnea and cardiovascular historySee reference 2
- 3. Use regulated formulations and the least burdensome effective routeSee reference 3
- 4. Track symptom response and therapy-specific safety markersSee reference 4
Troubleshooting
| Problem | Likely issue | Better next step |
|---|---|---|
| No symptom improvement | Diagnosis or dose may be wrong | Reassess rather than escalating automaticallySee reference 1,See reference 2 |
| High hematocrit on TRT | Excess erythropoietic effect | Prompt prescriber review is requiredSee reference 3,See reference 4 |
| Unexpected vaginal bleeding | Endometrial evaluation may be needed | Contact the clinician promptlySee reference 5,See reference 6 |
| Fertility plans change | TRT can suppress sperm | See a reproductive specialist before continuingSee reference 7,See reference 8 |
Safety and when to get medical help
Risks vary by therapy and include clotting, stroke, breast or endometrial effects, erythrocytosis, acne, edema, infertility, sleep-apnea worsening and drug-specific adverse effects. Do not use hormones from unverified online sources. Chest pain, one-sided leg swelling, stroke symptoms, severe headache, unexpected heavy bleeding or severe breathlessness needs urgent care.See reference 1,See reference 5,See reference 9
Who is most likely to benefit
Appropriately selected symptomatic menopausal women after individualized risk assessment.See reference 2,See reference 6
Men with pathological hypogonadism confirmed by symptoms, repeated accurate levels and cause evaluation.See reference 3,See reference 7
People seeking generic optimization without a diagnosis are more likely to face uncertain benefit and avoidable harm.See reference 4,See reference 8
Track five things
- Target symptomsSee reference 1
- Hormone level when relevantSee reference 3
- Blood count and prostate context for TRTSee reference 5
- Bleeding and breast or endometrial context for MHTSee reference 7
- Decision made after reviewing the resultSee reference 9
Frequently asked questions
Are bioidentical hormones safer?
A chemically identical regulated hormone can be appropriate, but custom-compounded products are not automatically safer or more effective.See reference 1
Does TRT reduce fertility?
Yes. Exogenous testosterone can markedly suppress sperm production.See reference 2
Does menopause HRT cause cancer?
Risk depends on hormone, regimen, route, duration and individual history; discuss the personalized absolute risk.See reference 3
Should levels be pushed to a young-adult maximum?
No guideline supports supraphysiological anti-aging targets.See reference 4
Does this extend lifespan?
No human trial has shown that hormone replacement therapy extends lifespan. Any longevity claim must be separated from evidence for a specific symptom, diagnosis or surrogate marker.See reference 5
How quickly should it work?
Use repeat morning fasting total testosterone and free testosterone when indicated.See reference 6
Can it replace standard treatment?
No. A complementary tool should not displace care already shown to reduce symptoms, complications or mortality.See reference 7
How do I know whether it helped?
Use a pre-defined outcome such as target symptoms and compare it with a baseline over an appropriate time window.See reference 8
Connect this decision to your wider health picture
LongevityMate helps organize measurements, symptoms, habits and trends so one test, device or treatment stays in context instead of becoming the whole plan.
See how LongevityMate worksReferences
- 1. Testosterone Therapy for Hypogonadism
Endocrine SocietyGuideline
- 2. Statement on Testosterone Replacement Therapy
Endocrine SocietyOfficial guidance
- 3. Hormone Therapy Position Statement
The Menopause SocietyGuideline
- 4. 2025 High Blood Pressure Guideline
American Heart AssociationGuideline
- 5. 2026 Guideline on the Management of Dyslipidemia
American Heart AssociationGuideline
- 6. Targeting Ageing With Rapamycin and Rapalogs
The Lancet Healthy LongevitySystematic review
- 7. Sterile Compounding and Injectable NAD
U.S. Food and Drug AdministrationOfficial guidance
- 8. Understanding Unapproved Use of Approved Drugs
U.S. Food and Drug AdministrationOfficial guidance
- 9. Warning About Unapproved Human Cell and Tissue Products
U.S. Food and Drug AdministrationOfficial guidance
- 10. Bulk Drug Substances With Significant Safety Risks
U.S. Food and Drug AdministrationOfficial guidance
Editorial transparency
- Published by
- LongevityMate Editorial Team
- Published
- Updated
Medical disclaimer
This guide provides general health education. It does not diagnose a condition, prescribe treatment, replace individualized medical care, or guarantee a health or longevity outcome.